RWA Wealth Partners LLC Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN

RWA Wealth Partners LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 57.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,598 shares of the biopharmaceutical company’s stock after selling 10,372 shares during the quarter. RWA Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $3,989,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Activest Wealth Management increased its position in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $31,000. Finally, Colonial Trust Advisors bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $657.53 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The stock has a 50-day moving average of $588.03 and a two-hundred day moving average of $568.04. The stock has a market cap of $69.69 billion, a P/E ratio of 15.75, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $834.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period last year, the business posted $12.46 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $796.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.